What is the official website of Hikma Pharmaceuticals ?

The official website of Hikma Pharmaceuticals is http://www.hikma.com.

What is Hikma Pharmaceuticals's cybersecurity risk score?

Hikma Pharmaceuticals has an AI-generated cybersecurity risk score of 768 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has Hikma Pharmaceuticals experienced?

According to Rankiteo, Hikma Pharmaceuticals currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Hikma Pharmaceuticals been affected by any supply chain cyber incidents ?

According to Rankiteo, Hikma Pharmaceuticals has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Hikma Pharmaceuticals have SOC 2 Type 1 certification ?

According to Rankiteo, Hikma Pharmaceuticals is not certified under SOC 2 Type 1.

Does Hikma Pharmaceuticals have SOC 2 Type 2 certification ?

According to Rankiteo, Hikma Pharmaceuticals does not hold a SOC 2 Type 2 certification.

Does Hikma Pharmaceuticals comply with GDPR ?

According to Rankiteo, Hikma Pharmaceuticals is not listed as GDPR compliant.

Does Hikma Pharmaceuticals have PCI DSS certification ?

According to Rankiteo, Hikma Pharmaceuticals does not currently maintain PCI DSS compliance.

Does Hikma Pharmaceuticals comply with HIPAA ?

According to Rankiteo, Hikma Pharmaceuticals is not compliant with HIPAA regulations.

Does Hikma Pharmaceuticals have ISO 27001 certification ?

According to Rankiteo,Hikma Pharmaceuticals is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Hikma Pharmaceuticals operate in ?

Hikma Pharmaceuticals operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does Hikma Pharmaceuticals have ?

Hikma Pharmaceuticals employs approximately 10,252 people worldwide.

Does Hikma Pharmaceuticals own any subsidiaries ?

Hikma Pharmaceuticals presently has no subsidiaries across any sectors.

How many LinkedIn followers does Hikma Pharmaceuticals have ?

Hikma Pharmaceuticals's official LinkedIn profile has approximately 637,630 followers.

What is the NAICS classification code for Hikma Pharmaceuticals ?

Hikma Pharmaceuticals is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does Hikma Pharmaceuticals have a Crunchbase profile ?

Yes, Hikma Pharmaceuticals has an official profile on Crunchbase, which can be accessed here: https://www.crunchbase.com/organization/hikma-pharmaceuticals.

Does Hikma Pharmaceuticals have a LinkedIn profile ?

Yes, Hikma Pharmaceuticals maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/hikma-pharmaceuticals.

How many cybersecurity incidents has Hikma Pharmaceuticals experienced ?

As of September 24, 2026, Rankiteo reports that Hikma Pharmaceuticals has not experienced any cybersecurity incidents.

How many peer or competitor companies does Hikma Pharmaceuticals have ?

Hikma Pharmaceuticals has an estimated 5,769 peer or competitor companies worldwide.

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

Hikma Pharmaceuticals

Boost Score +25 with badge (5 left)

768

/1000

Fair

793

/1000

Fair

Hikma Pharmaceuticals Vendor Cyber Rating & Cyber Score

hikma.com

cb in

Add Your Compliance Badge

For almost 50 years, we’ve been creating high-quality medicines and making them accessible to the people who need them. We are a trusted, reliable partner and dependable source of over 800* high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe. We have 29 manufacturing plants, 3 R&D hubs and c9,500 employees worldwide. *As of December 2025 Subscribe to our channel on YouTube https://youtube.com/@hikmapharmaceuticals5668 For all product information and enquiries, please contact us at [email protected]

Hikma Pharmaceuticals

Hikma Pharmaceuticals CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

No data available

Loading…

A.I.

Hikma Pharmaceuticals Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for Hikma Pharmaceuticals

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Hikma Pharmaceuticals in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Hikma Pharmaceuticals in 2026.

Incident Types Hikma Pharmaceuticals vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Hikma Pharmaceuticals in 2026.

Incident History - Hikma Pharmaceuticals (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Hikma Pharmaceuticals Subsidiaries

Parent Company

Hikma Pharmaceuticals

Pharmaceutical Manufacturing

Website: http://www.hikma.com

Company Size: 5,001-10,000 employees

No subsidiary data available for this company.

Loading…

Hikma Pharmaceuticals Similar Companies

Parexel

parexel.com

Parexel is a leading global clinical research organization (CRO) providing insights-driven Clinical and Consulting solutions to the world’s life sciences industry. Leveraging deep local knowledge and a global breadth of clinical, regulatory and therapeutic expertise, our 24,000+ professionals worldwide work in partnership with biopharmaceutical leaders, emerging innovators and sites to design and deliver clinical trials with patients in mind — broadening access and making clinical research a care option for anyone, anywhere. Our proven track record spans 40+ years and drives us forward, advancing clinical research in healthcare’s most complex areas while harnessing innovation to drive efficiencies across every phase of the clinical development process. Our insights-driven approach, proven delivery and trusted execution are accelerating the delivery of life-changing treatments to patients — With Heart.™ We continue to earn recognition industrywide, including the 2025 Scrip Award for “Best Contract Research Organization – Full-Service Provider,” 2024 Fierce Biotech CRO Award for "Innovative Approaches to Patient-Centric Research" and the 2024 and 2023 Society for Clinical Research Sites (SCRS) Eagle Award. Community Guidelines Because Parexel’s social media channels are open to the general public and employees, we are not responsible for views expressed other than our own. However, we do not tolerate posts that are: • Abusive, harassing or threatening to others. • Defamatory, offensive, obscene, vulgar or depicting violence. • Hateful targeting by race/ethnicity, age, color, creed, religion, gender, sexual preference or orientation, nationality or political beliefs. • Sexually explicit or pornographic. • Fraudulent, deceptive, libelous, misleading or unlawful. • Referencing criminal or illegal activity. • Spamming. We reserve the right to remove comments that do not adhere to our guidelines and report users who violate the rules of our page.

Merck Group

merckgroup.com

This channel is not intended for U.S. and Canadian visitors. Merck operates in the U.S. and Canada as EMD Serono in Healthcare, MilliporeSigma in Life Science and EMD Electronics in Electronics. An unaffiliated and unrelated company, Merck & Co., Inc., Kenilworth, NJ, US holds the rights in the trademark MERCK in the U.S. and Canada. _______________________________ We are Merck, a leading global science and technology company headquartered in Germany. We are curious explorers, courageous pioneers, and ingenious inventors. Our colleagues across the globe love innovating with science and technology to enrich people’s lives with our solutions in Life Science, Healthcare, and Electronics. Together, we dream big and are passionate about caring for our rich mix of people, customers, patients, and the planet. We believe in the positive power of science and technology. It has determined our actions since 1668 and inspires us to continue researching for a future worth living. As a family-owned company with over 350 years of experience, we stand for sustainability, responsibility, and innovative strength. We take pride in being a diverse and inclusive company that values and fosters the talents and abilities of our employees. That's why we are always looking for curious minds that see themselves imagining the unimaginable with us. Work your Magic and join Merck. Legal Disclaimer: www.merckgroup.com/en/legal-disclaimer.html Data Privacy Declaration: www.merckgroup.com/en/privacy-statement

Teva Pharmaceuticals

tevapharm.com

Teva Pharmaceuticals is a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how we make it happen, visit www.tevapharm.com. Our community guidelines may be found here: https://www.tevapharm.com/news-and-media/teva-social-media-guidelines/ Please note that adverse effects for any of our products should be reported at: https://www.tevapharm.com/teva-medical-information/report-a-side-effect-form/ Product-specific questions should be directed to Teva or Teva Group subsidiaries in your country. Contact details and Teva's Pharmacovigilance Privacy Policy may be found here: http://www.tevapharm.com/contact_us/

Eli Lilly and Company

lilly.com

We're a medicine company turning science into healing to make life better for people around the world. It all started nearly 150 years ago with a clear vision from founder Colonel Eli Lilly: "Take what you find here and make it better and better." Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing science to solve some of the world's most significant health challenges. General Information and Guidelines: When you engage with us on LinkedIn, you're agreeing to these Community Guidelines: https://e.lilly/guidelines. If you have questions about a Lilly medicine, contact The Lilly Answers Center at 1-800-Lilly-Rx (1-800-545-5979) Monday through Friday, excluding company holidays.

MANKIND PHARMA LTD

mankindpharma.com

Mankind Pharma, one of the top 5 leading pharmaceutical companies in India, started its journey in 1995. Today, we have an employee base of over 20,000 and are racing towards $1 Billion. At Mankind, we aspire to aid the community in leading a healthy life by formulating, developing, commercializing, and delivering affordable and accessible medicines that satisfy urgent medical needs. We take great pride in the success of our products ranging from Pharma, OTC and FMCG brands like Manforce Condoms, Manforce Tablets, Manforce Staylong Gel, Unwanted 72, Prega News, Gas-O-Fast, Kaloree 1, Kabzend, Acne Star Gel and many others. Our operations are in 34 overseas destinations across Asia, Africa, South-East Asia, Gulf countries and CIS countries. Our Vision - To be a global pharmaceutical company, most admired for its Affordability, Quality and Accessibility of products. Our Mission - To be able to provide cost-effective, innovation based superior quality pharmaceutical products across the globe, to improve the lives of the patients. Mankind strongly believes and follows its Core Values: 𝐂𝐮𝐬𝐭𝐨𝐦𝐞𝐫 𝐂𝐞𝐧𝐭𝐫𝐢𝐜𝐢𝐭𝐲: Commitment to Customer - Internal and External 𝐐𝐮𝐚𝐥𝐢𝐭𝐲: It is in our DNA to maintain and deliver highest quality standards and products 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧: Intensely Research driven organization aiming at product innovation and technology improvements 𝐈𝐧𝐭𝐞𝐠𝐫𝐢𝐭𝐲: Always trustworthy, widely respected to be honest, and believed by everyone 𝐆𝐨 𝐁𝐞𝐲𝐨𝐧𝐝: Aim higher than capabilities 𝐏𝐞𝐨𝐩𝐥𝐞 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 𝐚𝐧𝐝 𝐂𝐨𝐥𝐥𝐚𝐛𝐨𝐫𝐚𝐭𝐢𝐨𝐧: Together we are foreseeing future and diligently stimulating our people in attaining goals

Merck

merck.us

At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.merck.com. This site is intended for residents of the United States and Canada and their territories only. FLS: http://merck.us/3TKXNuZ

MENARINI Group

menarini.com

The Menarini Group is a leading international pharmaceutical and diagnostics company, with 140 years of history, present in 140 countries worldwide, with a turnover of 4.88 billion euro and more than 17,000 employees. With 9 centers for Research & Development, Menarini’s products are present in the most important therapeutic areas, including cardiology, oncology, gastroenterology, pneumology, diabetes, and anti-inflammatory/analgesics. The Group’s pharmaceutical production is carried out in its 18 manufacturing plants and is distributed across six continents. Menarini’s pharmaceutical production, in line with the highest quality standards, provides an ongoing contribution to the health of patients all over the world. For further information, please visit www.menarini.com For reading our Netiquette, please visit https://www.menarini.com/en-us/data-privacy/netiquette-of-menarini-group For reading our Privacy Notice for social networks users, please visit https://www.menarini.com/en-us/data-privacy/privacy-notice-for-social-network-users-of-menarini-group

Cipla

cipla.com

Cipla is a leading global pharmaceutical company trusted by healthcare professionals and patients across the world since 1935. A compassionate approach to healthcare that goes beyond the pursuit of profit and growth has been the force impelling Cipla’s history over the years. Our credo and our purpose of ‘Caring for Life' continues to guide our actions towards our people and the planet for creating a sustainable future. Cipla today has presence in 80+ countries, providing over 1,500 products across various therapeutic categories in 50+ dosage forms. Keeping with our legacy of care, we constantly strive to ensure access to high-quality medicines that make a difference in the lives of patients. Our paradigm-changing offer of a triple anti-retroviral (ARV) therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 was pivotal in bringing inclusiveness, accessibility and affordability to the centre of the HIV movement. An unmatched presence across the care continuum (awareness, prevention, diagnosis, treatment and adherence) and the widest range of drug-device combinations has established Cipla’s respiratory leadership in India and other key emerging markets. Armed with this legacy and a deep understanding of the lungs, we have articulated our aspiration to become a global lung leader and help millions breathe free.

Astellas Pharma

astellas.com

Astellas is a global life sciences company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases with high unmet medical need. Visit our Global Astellas LinkedIn Community Guidelines to learn more about interacting with this page: https://www.astellas.com/en/global-linkedin-community-guidelines

Loading…

NEWS

Hikma Pharmaceuticals CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

March 05, 2026 08:00 AM

How The Hikma Pharmaceuticals (LSE:HIK) Investment Story Is Shifting As Analyst Views Diverge

Hikma Pharmaceuticals is back in focus after its fair value estimate was trimmed from £21.82 to £20.47. This shift has put fresh attention...

Read Article

February 26, 2026 08:00 AM

Hikma Pharma's gloomy outlook kicks shares to more than three-year low

British generic drugmaker Hikma Pharmaceuticals scrapped its medium-term targets as it forecast slower annual revenue growth and profit on...

Read Article

February 06, 2026 08:00 AM

What Analysts Think Is Changing The Story For Hikma Pharmaceuticals (LSE:HIK)

The latest update on Hikma Pharmaceuticals focuses on the price target, with the modelled fair value held at 22.14 while core assumptions...

Read Article

January 08, 2026 08:00 AM

Looking At The Narrative For Hikma Pharmaceuticals LSE HIK After Analyst Split On Fair Value

Hikma Pharmaceuticals' fair value estimate has been nudged down from £22.66 to £22.00 per share, a small adjustment that better reflects the...

Read Article

December 16, 2025 08:00 AM

The Character of the Corporation 2025: Navigating Tumultuous Times for Multinational Businesses

Directors Nina Henderson and John Zangardi on the key differences between serving on multinational and domestic boards.

Read Article

December 15, 2025 08:00 AM

How the Narrative Around Hikma Pharmaceuticals Is Shifting After Recent Analyst Target Moves

Hikma Pharmaceuticals' latest valuation update points to a slightly lower fair value estimate of about $22.66 per share, even as analysts...

Read Article

November 28, 2025 08:00 AM

How Recent Developments Are Shaping the Hikma Pharmaceuticals Story and Its Valuation

Hikma Pharmaceuticals' consensus analyst price target has seen a slight dip, moving from £23.55 to £23.36 per share.

Read Article

November 13, 2025 08:00 AM

Why The Narrative Around Hikma Pharmaceuticals Is Shifting After Recent Analyst Updates

Hikma Pharmaceuticals has recently seen its fair value estimate reduced from £25.40 to £23.55, as analysts update their assessments in light...

Read Article

September 19, 2025 07:00 AM

Hikma Pharmaceuticals PLC (LON:HIK) is favoured by institutional owners who hold 59% of the company

Key Insights Institutions' substantial holdings in Hikma Pharmaceuticals implies that they have significant influence...

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-96680

SUMMARY

A vulnerability was detected in ByteDance Coze Scraper Extension up to 2.0.2. Affected by this vulnerability is the function chrome.runtime.onMessageExternal.addListener of the file static/background/index.js of the component External Message Handler. The manipulation of the argument body.url/paginationConfig/xPathConfig/body.urls/xPaths results in missing authorization. The attack can be launched remotely. The exploit is now public and may be used. The vendor was contacted early about this disclosure but did not respond in any way.

Published

Date2026-09-23

Updated

Date2026-09-23

RISK INFORMATION (Score: 4.3)

cvss2

Base Score: 5.0

Complexity: LOW

AV:N/AC:L/Au:N/C:P/I:N/A:N

cvss3

Base Score: 4.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:U/C:L/I:N/A:N

cvss4

Base Score: 2.1

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:P/VC:L/VI:N/VA:N/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

1.4

Exploitability

2.8

REFERENCES

CVE-2026-96678

SUMMARY

A security vulnerability has been detected in weiqingwen spring-boot-forum up to 538eecc3c6b85fdf0768ab4e8354b48c0c17d94f. Affected is the function validate of the file src/main/java/com/qingwenwei/util/NewUserFormValidator.java of the component Avatar Upload. The manipulation of the argument Username leads to path traversal. The attack can be initiated remotely. The exploit has been disclosed publicly and may be used. Continious delivery with rolling releases is used by this product. Therefore, no version details of affected nor updated releases are available. The vendor was contacted early about this disclosure but did not respond in any way.

Published

Date2026-09-23

Updated

Date2026-09-23

RISK INFORMATION (Score: 6.3)

cvss2

Base Score: 6.5

Complexity: LOW

AV:N/AC:L/Au:S/C:P/I:P/A:P

cvss3

Base Score: 6.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:L/I:L/A:L

cvss4

Base Score: 2.1

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.4

Exploitability

2.8

REFERENCES

CVE-2026-96676

SUMMARY

A vulnerability was identified in Fast FAC1900R 20190827_2.0.2. The impacted element is the function get_alias_name of the component uhttpd. Such manipulation leads to stack-based buffer overflow. The attack may be performed from remote. The exploit is publicly available and might be used. The vendor was contacted early about this disclosure but did not respond in any way.

Published

Date2026-09-23

Updated

Date2026-09-23

RISK INFORMATION (Score: 6.3)

cvss2

Base Score: 6.5

Complexity: LOW

AV:N/AC:L/Au:S/C:P/I:P/A:P

cvss3

Base Score: 6.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:L/I:L/A:L

cvss4

Base Score: 2.1

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.4

Exploitability

2.8

REFERENCES

CVE-2026-96606

SUMMARY

A security flaw has been discovered in LB-Link BL-CPE600EU 5.8.13. This vulnerability affects unknown code of the file Mifi_config.bin of the component Configuration Backup Handler. The manipulation results in information disclosure. The attack can be launched remotely. The exploit has been released to the public and may be used for attacks. The vendor was contacted early about this disclosure but did not respond in any way.

Published

Date2026-09-23

Updated

Date2026-09-23

RISK INFORMATION (Score: 5.3)

cvss2

Base Score: 5.0

Complexity: LOW

AV:N/AC:L/Au:N/C:P/I:N/A:N

cvss3

Base Score: 5.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:L/I:N/A:N

cvss4

Base Score: 5.5

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:L/VI:N/VA:N/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

1.4

Exploitability

3.9

REFERENCES

CVE-2026-70125

SUMMARY

Microsoft Outlook Remote Code Execution Vulnerability

Published

Date2026-09-23

Updated

Date2026-09-23

RISK INFORMATION (Score: 8.8)

cvss3

Base Score: 8.8

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:U/C:H/I:H/A:H

Impact Score

5.9

Exploitability

2.8

REFERENCES

https://msrc.microsoft.com/update-guide/vulnerability/CVE-2026-70125

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…

Badge your company to reduce your risk score and your cyber insurance costs!

Trusted by insurers. Chosen by leaders.

Hikma Pharmaceuticals Vendor Cyber Rating & Cyber Score

Hikma Pharmaceuticals A.I CyberSecurity Scoring

Hikma Pharmaceuticals CyberSecurity News & History

Hikma Pharmaceuticals Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Incident Predictions locked

A.I Risk Score Likelihood 3 - 6 - 9 months

A.I. Risk Score Predictions locked

Underwriter Stats for Hikma Pharmaceuticals

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incidents vs All-Companies Average (This Year)

Incident Types Hikma Pharmaceuticals vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incident History - Hikma Pharmaceuticals (X = Date, Y = Severity)

Hikma Pharmaceuticals Subsidiaries

Parent Company

Hikma Pharmaceuticals

Hikma Pharmaceuticals Similar Companies

Parexel

Merck Group

Teva Pharmaceuticals

Eli Lilly and Company

MANKIND PHARMA LTD

Merck

MENARINI Group

Cipla

Astellas Pharma

Hikma Pharmaceuticals CyberSecurity News

How The Hikma Pharmaceuticals (LSE:HIK) Investment Story Is Shifting As Analyst Views Diverge

Hikma Pharma's gloomy outlook kicks shares to more than three-year low

What Analysts Think Is Changing The Story For Hikma Pharmaceuticals (LSE:HIK)

Looking At The Narrative For Hikma Pharmaceuticals LSE HIK After Analyst Split On Fair Value

The Character of the Corporation 2025: Navigating Tumultuous Times for Multinational Businesses

How the Narrative Around Hikma Pharmaceuticals Is Shifting After Recent Analyst Target Moves

How Recent Developments Are Shaping the Hikma Pharmaceuticals Story and Its Valuation

Why The Narrative Around Hikma Pharmaceuticals Is Shifting After Recent Analyst Updates

Hikma Pharmaceuticals PLC (LON:HIK) is favoured by institutional owners who hold 59% of the company

Global CVEs (Not Company-Specific)

Access Data Using Our API

What Do We Measure ?

These are some of the factors we use to calculate the overall score:

Rankiteo

Hikma Pharmaceuticals CyberSecurity News & History

Hikma Pharmaceuticals Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Incident Predictions locked

A.I Risk Score Likelihood 3 - 6 - 9 months

A.I. Risk Score Predictions locked

Underwriter Stats for Hikma Pharmaceuticals

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incidents vs All-Companies Average (This Year)

Incident Types Hikma Pharmaceuticals vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incident History - Hikma Pharmaceuticals (X = Date, Y = Severity)

Hikma Pharmaceuticals Subsidiaries

Parent Company

Hikma Pharmaceuticals

Hikma Pharmaceuticals Similar Companies

Parexel

Merck Group

Teva Pharmaceuticals

Eli Lilly and Company

MANKIND PHARMA LTD

Merck

MENARINI Group

Cipla

Astellas Pharma

Hikma Pharmaceuticals CyberSecurity News

How The Hikma Pharmaceuticals (LSE:HIK) Investment Story Is Shifting As Analyst Views Diverge

Hikma Pharma's gloomy outlook kicks shares to more than three-year low

What Analysts Think Is Changing The Story For Hikma Pharmaceuticals (LSE:HIK)

Looking At The Narrative For Hikma Pharmaceuticals LSE HIK After Analyst Split On Fair Value

The Character of the Corporation 2025: Navigating Tumultuous Times for Multinational Businesses

How the Narrative Around Hikma Pharmaceuticals Is Shifting After Recent Analyst Target Moves

How Recent Developments Are Shaping the Hikma Pharmaceuticals Story and Its Valuation

Why The Narrative Around Hikma Pharmaceuticals Is Shifting After Recent Analyst Updates

Hikma Pharmaceuticals PLC (LON:HIK) is favoured by institutional owners who hold 59% of the company

Global CVEs (Not Company-Specific)

Access Data Using Our API

What Do We Measure ?